Table 1 Basal clinicopathologic characteristics in training set and test set.
From: A novel prognostic model based on migrasome-related LncRNAs for gastric cancer
Covariates | Type | Total N = 407 | Training N1 = 204 | Test N2 = 203 | P-value |
|---|---|---|---|---|---|
Age | <=65 | 183(44.96%) | 90(44.12%) | 93(45.81%) | 0.8416 |
Age | > 65 | 221(54.3%) | 112(54.9%) | 109(53.69%) | |
Age | Unknown | 3(0.74%) | 2(0.98%) | 1(0.49%) | |
Gender | Female | 144(35.38%) | 70(34.31%) | 74(36.45%) | 0.7281 |
Gender | Male | 263(64.62%) | 134(65.69%) | 129(63.55%) | |
Grade | G1 | 12(2.95%) | 5(2.45%) | 7(3.45%) | 0.5581 |
Grade | G2 | 144(35.38%) | 77(37.75%) | 67(33%) | |
Grade | G3 | 242(59.46%) | 118(57.84%) | 124(61.08%) | |
Grade | Unknown | 9(2.21%) | 4(1.96%) | 5(2.46%) | |
Stage | Stage I | 55(13.51%) | 29(14.22%) | 26(12.81%) | 0.7812 |
Stage | Stage II | 122(29.98%) | 59(28.92%) | 63(31.03%) | |
Stage | Stage III | 167(41.03%) | 86(42.16%) | 81(39.9%) | |
Stage | Stage IV | 39(9.58%) | 17(8.33%) | 22(10.84%) | |
Stage | Unknown | 24(5.9%) | 13(6.37%) | 11(5.42%) | |
T | T1 | 21(5.16%) | 14(6.86%) | 7(3.45%) | 0.3347 |
T | T2 | 86(21.13%) | 41(20.1%) | 45(22.17%) | |
T | T3 | 179(43.98%) | 84(41.18%) | 95(46.8%) | |
T | T4 | 113(27.76%) | 59(28.92%) | 54(26.6%) | |
T | Unknown | 8(1.97%) | 6(2.94%) | 2(0.99%) | |
M | M0 | 362(88.94%) | 185(90.69%) | 177(87.19%) | 0.4467 |
M | M1 | 26(6.39%) | 10(4.9%) | 16(7.88%) | |
M | Unknown | 19(4.67%) | 9(4.41%) | 10(4.93%) | |
N | N0 | 121(29.73%) | 57(27.94%) | 64(31.53%) | 0.2844 |
N | N1 | 108(26.54%) | 58(28.43%) | 50(24.63%) | |
N | N2 | 77(18.92%) | 43(21.08%) | 34(16.75%) | |
N | N3 | 82(20.15%) | 35(17.16%) | 47(23.15%) | |
N | Unknown | 19(4.67%) | 11(5.39%) | 8(3.94%) |
